A3981

Sigma-Aldrich

Monoclonal Anti-β-Amyloid antibody produced in mouse

clone BAM-10, purified from hybridoma cell culture

Synonym(s):
Anti-A-BETA, Anti-Amyloid β Precursor Protein, Clone BAM91
MDL number:
NACRES:
NA.41
Pricing and availability is not currently available.

Quality Level

biological source

mouse

antibody form

purified immunoglobulin

antibody product type

primary antibodies

clone

BAM-10, monoclonal

form

buffered aqueous solution

species reactivity

human

packaging

antibody small pack of 25 μL

concentration

~1.5 mg/mL

application(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 2.5-5 μg/mL using formic-acid treated tissue sections of human Alzheimer disease brain tissue
indirect ELISA: suitable
western blot: suitable

isotype

IgG1

conjugate

unconjugated

UniProt accession no.

shipped in

dry ice

storage temp.

−20°C

Gene Information

human ... APP(351), APP(351)

Looking for similar products? Visit Product Comparison Guide

General description

The antibody reacts specifically with β-amyloid protein. The epitope recognized by the antibody resides within amino acids 1-12 of the β-amyloid protein. It specifically stains amyloid plaques within the cortex and amyloid deposits in blood vessels using formic acid-treated, formalin-fixed, paraffin-embedded, and Methacarn-fixed sections of human Alzheimer′s disease (AD) brain tissue.
β-amyloid gene is located on human chromosome 21q21.
The β-amyloid precursor protein (APP) is cleaved sequentially by the proteolytic enzymes β-and γ-secretase to produce β-amyloid (Aβ) peptides with the Aβ1-42 and the Aβ1-40 forms being the most prevalent. Secreted Aβ peptides are degraded either via a re-uptake mechanism followed by endosomal degradation, or by an extracellular insulin degrading enzyme. Extracellular accumulation of Aβ leads to the formation of aggregates, fibrils and eventually amyloid deposits called neuritic plaques, which is the hallmark of Alzheimer′s disease (AD).

Immunogen

Synthetic β-amyloid peptide, conjugated to KLH.

Application

The antibody is useful in immunohistochemistry, immunoblotting, ELISA, and competitive ELISA. Also, this antibody has been used to neutralize Aβ assemblies in brains of transgenic mice expressing a mutant form of amyloid precursor protein, and for in vivo deep tissue imaging using near-IR optical spectrum.
Mouse monoclonal anti-ABETA was used to treat old WT PDAPP mice with amyloid accumulation and learning deficits in an attempt to improve learning and decrease accumulation, however no response was observed.
Monoclonal Anti-β-Amyloid antibody has been used in immunoprecipitation analysis, microarray-based immunoassay and microarray.

Biochem/physiol Actions

β-amyloid gene acts as the substrate of insulin-degrading enzyme (IDE). It plays a major role in the pathogenesis of Alzheimer′s disease (AD) and type 2 diabetes mellitus (DM2).

Physical form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Personal Protective Equipment

dust mask type N95 (US),Eyeshields,Gloves

RIDADR

NONH for all modes of transport

WGK Germany

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Interactions of pathological hallmark proteins: Tubulin polymerization promoting protein/p25, β-amyloid and α-synuclein.
Olah J, et al.
The Journal of Biological Chemistry, jbc-M111 (2011)
Application of immunosignatures to the assessment of Alzheimer's disease.
Restrepo L, et al.
Annals of Neurology, 70(2), 286-295 (2011)
Lih-Fen Lue et al.
Neurology and therapy, 8(Suppl 2), 95-111 (2019-12-14)
New super-sensitive biomarker assay platforms for measuring Alzheimer's disease (AD) core pathological markers in plasma have recently been developed and tested. Research findings from these technologies offer promising evidence for identifying the earliest stages of AD and correlating them with...
Ming-Jang Chiu et al.
Nanomedicine : nanotechnology, biology, and medicine, 28, 102182-102182 (2020-03-31)
Blood-based biomarker assays of plasma β-amyloid (Aβ) and tau have the advantages of cost-effective and less invasive for the diagnosis of Alzheimer's disease (AD). We used two independent cohorts to cross-validate the clinical use of the nanoparticle-based immunomagnetic assay of...
Ling-Yun Fan et al.
Frontiers in aging neuroscience, 10, 175-175 (2018-07-04)
Background: Neuritic plaques and neurofibrillary tangles are the pathological hallmarks of Alzheimer's disease (AD), while the role of brain amyloid deposition in the clinical manifestation or brain atrophy remains unresolved. We aimed to explore the relation between brain amyloid deposition...
Articles
Alzheimer's disease (AD) is the most common cause of dementia in the elderly and is characterized by gradual loss of cognitive functions.
Read More

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.